WO2002004509A3 - Genexpression, genomalteration und reporterexpression in myofibroblasten und myofibroblast-ähnlichen zellen - Google Patents

Genexpression, genomalteration und reporterexpression in myofibroblasten und myofibroblast-ähnlichen zellen Download PDF

Info

Publication number
WO2002004509A3
WO2002004509A3 PCT/EP2001/007913 EP0107913W WO0204509A3 WO 2002004509 A3 WO2002004509 A3 WO 2002004509A3 EP 0107913 W EP0107913 W EP 0107913W WO 0204509 A3 WO0204509 A3 WO 0204509A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
expression
cells
specific
myofibroblast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/007913
Other languages
English (en)
French (fr)
Other versions
WO2002004509A2 (de
Inventor
Margarete Odenthal
Diana Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00128446A external-priority patent/EP1172375A1/de
Application filed by Individual filed Critical Individual
Priority to JP2002509372A priority Critical patent/JP2004502448A/ja
Priority to US10/332,733 priority patent/US20040106565A1/en
Priority to AU2001283937A priority patent/AU2001283937A1/en
Priority to EP01962847A priority patent/EP1315748A2/de
Publication of WO2002004509A2 publication Critical patent/WO2002004509A2/de
Publication of WO2002004509A3 publication Critical patent/WO2002004509A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)

Abstract

Die Erfindung betrifft spezifische, regulatorische Sequenzbereiche des alpha Smooth Muscle Aktin-Gens (a-SMA-Gens), Fusionskonstrukte, in denen solche regulatorische Sequenzbereiche des a-SMA-Gens mit weiteren funktionellen Nukleinsäuresequenzen operativ verknüpft sind, sowie die Verwendung solcher regulatorischer Sequenzbereiche zur zelltyp- und differenzierungspezifischen Reporterexpression, zu zelltyp- und differenzierungsspezifischen Genveränderungen (Alteration, Mutation) und zu Genexpressionsveränderungen in Zellen und Organismen.
PCT/EP2001/007913 2000-07-11 2001-07-10 Genexpression, genomalteration und reporterexpression in myofibroblasten und myofibroblast-ähnlichen zellen Ceased WO2002004509A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002509372A JP2004502448A (ja) 2000-07-11 2001-07-10 筋線維芽細胞及び筋線維芽細胞様細胞における遺伝子発現、ゲノム改変、並びにレポーター発現
US10/332,733 US20040106565A1 (en) 2000-07-11 2001-07-10 Gene expression, genome alteration and reporter expression in myofibroblasts and myofibroblast-like cells
AU2001283937A AU2001283937A1 (en) 2000-07-11 2001-07-10 Gene expression, genome alteration and reporter expression in myofibroblasts and myofibroblast-like cells
EP01962847A EP1315748A2 (de) 2000-07-11 2001-07-10 Genexpression, genomalteration und reporterexpression in myofibroblasten und myofibroblast-ähnlichen zellen

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE10033633 2000-07-11
DE10033633.7 2000-07-11
DE10053879.7 2000-10-31
DE10053879A DE10053879A1 (de) 2000-07-11 2000-10-31 Genexpression, Genomalteration und Reporterexpression in Myofibroblasten und myofibroblast-ähnlichen Zellen
EP00128446A EP1172375A1 (de) 2000-07-11 2000-12-22 Genexpression, Genomalteration und Reporterexpression in Myofibroblasten und Myofibroblast-ähnlichen Zellen durch Verwendung der regulatorischen Bereiche des Alpha Smooth Muscle Aktin-Gens
EP00128446.2 2000-12-22

Publications (2)

Publication Number Publication Date
WO2002004509A2 WO2002004509A2 (de) 2002-01-17
WO2002004509A3 true WO2002004509A3 (de) 2002-08-01

Family

ID=7648527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/007913 Ceased WO2002004509A2 (de) 2000-07-11 2001-07-10 Genexpression, genomalteration und reporterexpression in myofibroblasten und myofibroblast-ähnlichen zellen

Country Status (6)

Country Link
US (1) US20040106565A1 (de)
EP (1) EP1315748A2 (de)
JP (1) JP2004502448A (de)
AU (1) AU2001283937A1 (de)
DE (1) DE10053879A1 (de)
WO (1) WO2002004509A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1875103A (zh) * 2003-08-29 2006-12-06 宝生物工程株式会社 筛选功能核苷酸分子的方法
WO2014139884A2 (en) * 2013-03-14 2014-09-18 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024254A1 (en) * 1998-10-23 2000-05-04 University Of Virginia Patent Foundation Compositions and methods for modulating expression within smooth muscle cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885769A (en) * 1991-02-14 1999-03-23 Schering Corporation Screening systems

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024254A1 (en) * 1998-10-23 2000-05-04 University Of Virginia Patent Foundation Compositions and methods for modulating expression within smooth muscle cells

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BLANK R S ET AL: "ELEMENTS OF THE SMOOTH MUSCLE ALPHA-ACTIN PROMOTER REQUIRED IN CIS FOR TRANSCRIPTIONAL ACTIVATION IN SMOOTH MUSCLE. EVIDENCE FOR CELL TYPE-SPECIFIC REGULATION", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 267, no. 2, 15 January 1992 (1992-01-15), pages 984 - 989, XP002923256, ISSN: 0021-9258 *
CARROLL S L ET AL: "STRUCTURE AND COMPLETE NUCLEOTIDE SEQUENCE OF THE CHICKEN ALPHA-SMOOTH MUSCLE AORTIC ACTIN GENE AN ACTIN GENE WHICH PRODUCES MULTIPLE MESSENGER RNA SPECIES", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 261, no. 19, 1986, pages 8965 - 8976, XP000998146, ISSN: 0021-9258 *
COGAN JOHN G ET AL: "Plasticity of vascular smooth muscle alpha-actin gene transcription: Characterization of multiple, single-, and double-strand specific DNA-binding proteins in myoblasts and fibroblasts.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 19, 1995, pages 11310 - 11321, XP000993134, ISSN: 0021-9258 *
JUNG FRANK ET AL: "Characterization of an E-box-dependent cis element in the smooth muscle alpha-actin promoter.", ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, vol. 19, no. 11, November 1999 (1999-11-01), pages 2591 - 2599, XP000998280, ISSN: 1079-5642 *
MIN B ET AL: "THE 5'-FLANKING REGION OF THE MOUSE VASCULAR SMOOTH MUSCLE ALPHA ACTIN GENE CONTAINS EVOLUTIONARILY CONSERVED SEQUENCE MOTIFS WITHIN A FUNCTIONAL PROMOTER", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 27, 1990, pages 16667 - 16675, XP000992808, ISSN: 0021-9258 *
NAKANO Y ET AL: "TRANSCRIPTIONAL REGULATORY ELEMENTS IN THE 5' UPSTREAM AND FIRST INTRON REGIONS OF THE HUMAN SMOOTH MUSCLE AORTIC TYPE ALPHA ACTIN-ENCODING GENE", GENE (AMSTERDAM), vol. 99, no. 2, 1991, pages 285 - 290, XP000992809, ISSN: 0378-1119 *
SAGA HIROSHI ET AL: "Phenotype-dependent expression of alpha-smooth muscle actin in visceral smooth muscle cells.", EXPERIMENTAL CELL RESEARCH, vol. 247, no. 1, 25 February 1999 (1999-02-25), pages 279 - 292, XP000998496, ISSN: 0014-4827 *

Also Published As

Publication number Publication date
JP2004502448A (ja) 2004-01-29
EP1315748A2 (de) 2003-06-04
AU2001283937A1 (en) 2002-01-21
WO2002004509A2 (de) 2002-01-17
US20040106565A1 (en) 2004-06-03
DE10053879A1 (de) 2002-02-07

Similar Documents

Publication Publication Date Title
WO2003080807A8 (en) Compositions and methods for suppressing eukaryotic gene expression
WO2002000894A3 (en) Gene silencing vector
WO2002008409A3 (en) Methods for the replacement, translocation and stacking of dna in eukaryotic genomes
WO2002042424A3 (en) Seed-preferred regulatory elements and uses thereof
WO2002006457A3 (en) Novel lipase genes
CA2465156A1 (en) Il-21 antagonists
EE200300100A (et) Polüpeptiid, selle kodeerivat nukleotiidjärjestust sisaldav nukleiinhape, vektor ja peremeesrakk, meetod polüpeptiidi valmistamiseks ning farmatseutiline kompositsioon
WO2002095014A3 (en) Polypeptides having cellobiase activity and polynucleotides encoding same
WO2000040615A3 (en) EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS
WO2001079463A3 (en) Nucleic acids encoding polypeptides having haloperoxidase activity
WO2005021585A3 (en) Axmi-003, a delta-endotoxin gene and methods for its use
EP1005540A4 (de) Ikk-beta proteines, nukleinsäuren und verfahren
WO2002086090A3 (en) Identification of essential genes of aspegillus fumigatus and methods of use
WO2006060062A3 (en) Trichoderma reesei glucoamylase and homologs thereof
WO2003008575A3 (en) Dna sequences for regulating transcription
WO2001083796A3 (en) Adenoviral vectors for tumor specific gene expression and uses thereof
WO2004067709A3 (en) Identification of essential genes of aspergillus fumigatus and methods of use
DE69930515D1 (de) Polyketide, ihre herstellung, und darin benutzte materialien
WO2002044361A3 (en) Eukaryotic expression libraries based on double lox recombination and methods of use
WO2001077334A3 (fr) Genome de lactococcus lactis, polypeptides et utilisations
JP2005532815A5 (de)
WO2002004509A3 (de) Genexpression, genomalteration und reporterexpression in myofibroblasten und myofibroblast-ähnlichen zellen
WO2001061021A3 (en) Transgenic plants having resistance to a fungal disease
Lapeyre et al. Nucleotide sequence of the Schizosaccharomyces pombe 25S ribosomal RNA and its phylogenetic implications
WO2002006508A3 (en) CYCLOMALTODEXTRIN GLUCANOTRANSFERASE (CGTase9, DNA SEQUENCE ENCODING IT AND USES THEREOF

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001962847

Country of ref document: EP

Ref document number: 2001283937

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001962847

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10332733

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001962847

Country of ref document: EP